Verve Therapeutics Inc (NASDAQ: VERV) is -47.56% lower on its value in year-to-date trading and has touched a low of $7.36 and a high of $21.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VERV stock was last observed hovering at around $7.60 in the last trading session, with the day’s loss setting it -0.29%.
Currently trading at $7.31, the stock is -33.53% and -42.24% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.37 million and changing -3.82% at the moment leaves the stock -46.82% off its SMA200. VERV registered -53.41% loss for a year compared to 6-month gain of -36.49%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -46.25% loss in the last 1 month and extending the period to 3 months gives it a -42.76%, and is -12.98% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.83% over the week and 7.14% over the month.
Verve Therapeutics Inc (VERV) has around 255 employees, a market worth around $574.20M and $11.76M in sales. Profit margin for the company is -1701.55%. Distance from 52-week low is -0.74% and -65.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.12%).
The EPS is expected to grow by 7.64% this year.
Verve Therapeutics Inc (VERV) Top Institutional Holders
The shares outstanding are 81.97M, and float is at 54.79M with Short Float at 28.03%.
Verve Therapeutics Inc (VERV) Insider Activity
The most recent transaction is an insider sale by Nickerson Joan,the company’sChief Administrative Officer. SEC filings show that Nickerson Joan sold 1,514 shares of the company’s common stock on Apr 02 ’24 at a price of $8.24 per share for a total of $12475.0. Following the sale, the insider now owns 8659.0 shares.
Verve Therapeutics Inc disclosed in a document filed with the SEC on Nov 29 ’23 that Dorval Allison (Chief Financial Officer) sold a total of 554 shares of the company’s common stock. The trade occurred on Nov 29 ’23 and was made at $11.45 per share for $6343.0. Following the transaction, the insider now directly holds 4060.0 shares of the VERV stock.
